Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 5, 2000, Pages 1169-1176

  Turner, Bruce C ^a   Gumbs, Andrew A ^b   Carter, Darryl ^c   Glazer, Peter M ^b   Haffty, Bruce G ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Department Oftherapeutic Radiology ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cell cycle regulator; Cyclin D1; Radiosensitivity

Indexed keywords

CYCLIN D1; POLYCLONAL ANTIBODY; PROTEIN ANTIBODY;

ADULT; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL CYCLE; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; RELAPSE; STATISTICAL ANALYSIS; SURVIVAL;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL NUCLEUS; COMBINED MODALITY THERAPY; CYCLIN D1; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0034662303     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00525-3     Document Type: Article

References (33)

1. Veronesi U., Saccozzi R., Del Vecchio M., et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 305:1981;6-11.
2. Fischer B., Redmond C., Poisson R., et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 320:1989;822-828.
3. Stotter A.T., McNeese M.D., Ames F.C., et al. Predicting the rate and extent of locoregional failure after breast conservation therapy for early breast cancer. Cancer. 64:1989;2217-2225.
4. Haffty B.G., Fischer D., Beinfield M., et al. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 21:1991;293-298.
5. Lichter A.S., Lippman M.E., Danforth D. Jr, et al. Mastectomy versus breast conserving therapy in the treatment of stage I and II carcinoma of the breast A randomized trial at the National Cancer Institute . J Clin Oncol. 10:1992;976-983.
6. Haffty B.G., Reiss M., Beinfield M., et al. Ipsilateral breast tumor recurrence as a predictor of distant disease Implications for systemic therapy at the time of local relapse . J Clin Oncol. 14:1996;52-57.
7. Fourquet A., Campana F., Zafrani B., et al. Prognostic factors in the conservative management of early breast cancer A 25 year follow-up at the Institute Curie . Int J Radiat Oncol Biol Phys. 17:1989;719-725.
8. Kurtz J.M., Jacquemier J., Amalric R., et al. Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer. 65:1990;1867-1878.
9. Kurtz J.M., Spitalier J.M., Amalric R., et al. Mammary recurrences in women younger than forty. Int J Radiat Oncol Biol Phys. 15:1988;271-276.
10. Borger J., Kemperman H., Hart A., et al. Risk factors in breast-conservation therapy. J Clin Oncol. 12:1994;653-660.
11. Schnitt SJ, Connolly JL, Harris JR; et al. Pathologic predictors or early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer 53;1049-1057.
12. Turner B.C., Haffty B.G., Narayanan L., et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57:1997;3079-3083.
13. Haffty B.G., Brown F., Carter D., et al. Evaluation of HER-2 NEU oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer A case-control study . Int J Radiat Oncol Biol Phys. 35:1996;751-757.
14. Buckley M.F., Sweeney K.J., Hamilton J.A., et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 8:1993;2127-2133.
15. Bartkova J., Lukas J., Muller H., et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 57:1994;353-361.
16. Gillett C., Fantl V., Smith R., et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1994;1812-1817.
17. 1 to complete the cell cycle. Proc Natl Acad Sci USA. 91:1994;8022-8026.
18. Bartkov J., Lukas J., Strauss M., et al. Cell cycle variation and tissue-restricted expression of human cyclin D1 protein. J Pathol. 172:1994;237-245.
19. Quelle D.E., Ashmun R.A., Shurtleff S.A., et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Devel. 7:1993;1559-1571.
20. Kranenburg O, van der Eb AJ, Zantema A: Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 1996;15:46-54.
21. de Jong J.S., van Diest P.J., Michalides R.J., et al. Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer. Mol Path. 51:1998;30-34.
22. Wang T.C., Cardiff R.D., Zukerberg L., et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 369:1994;669-671.
23. Martin Coco J.M., Balkenende A., Verschoor T., et al. Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res. 59:1999;1134-1140.
24. Gillett C., Smith P., Gregory W., et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 69:1996;92-99.
25. McIntosh G.G., Anderson J.J., Milton I., et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 11:1995;885-891.
26. Schuuring E., Verhoeven E., van Tinteren H. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 52:1992;5229-5234.
27. Maher M.G., Sapi E., Turner B., et al. Prognostic significance of colony-stimulating factor expression in ipsilateral breast cancer recurrence. Clin Cancer Res. 4:1998;1851-1856.
28. King W.J., DeSombre E.R., Jensen E.V., et al. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res. 45:1985;293-296.
29. Haffty B.G., Carter D., Flynn S.G., et al. Local recurrence versus new primary Clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting . Int J Radiat Oncol Biol Phys. 27:1993;575-583.
30. Weinstat-Saslow D., Merino M.J., Manrow R.E., et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med. 1:1995;1257-1260.
31. Peters G., Fantl V., Smith R., et al. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat. 33:1995;125-135.
32. Hui R., Cornish A.L., McClelland R.A., et al. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clinical Cancer Res. 2:1996;923-928.
33. Kurtz J.M., Spitalier J.M., Amalric R., et al. The prognostic significance of late local recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 18:1990;87-93.